Korro Bio's quarterly cash and cash equivalents
increased
from Jun. 2022 ($0.00 Mil) to Dec. 2022 ($36.33 Mil) and
increased
from Dec. 2022 ($36.33 Mil) to Jun. 2023 ($59.33 Mil).
Korro Bio's annual cash and cash equivalents
declined
from Dec. 2021 ($83.49 Mil) to Dec. 2022 ($36.33 Mil) but then
increased
from Dec. 2022 ($36.33 Mil) to Dec. 2023 ($166.15 Mil).
Korro Bio Cash And Cash Equivalents Historical Data
The historical data trend for Korro Bio's Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Korro Bio Cash And Cash Equivalents Chart
Korro Bio Annual Data
Trend
Dec21
Dec22
Dec23
Cash And Cash Equivalents
83.49
36.33
166.15
Korro Bio Semi-Annual Data
Dec21
Jun22
Dec22
Jun23
Dec23
Cash And Cash Equivalents
83.49
-
36.33
59.33
166.15
Korro Bio Cash And Cash Equivalents Calculation
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Korro Bio (NAS:KRRO) Cash And Cash Equivalents Explanation
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
Korro Bio Cash And Cash Equivalents Related Terms
Thank you for viewing the detailed overview of Korro Bio's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
KRRO has been successfully added to your